Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

Bone Marrow Transplantation

Volumn 25, Issue 10, 2000, Pages 1021-1028

  Nagler, A ^a   Slavin, S ^a   Varadi, G ^a   Naparstek, E ^a   Samuel, S ^a   Or, R ^a   Mandigers, C M ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic; Conditioning regimen; Fludarabine; Low intensity; Malignant lymphoma; Peripheral blood stem cell transplantation

Indexed keywords

FLUDARABINE;

ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOXICITY; FEMALE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LUNG INSUFFICIENCY; LUNG TOXICITY; LYMPHOMA; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; ORGAN DONOR; PRIORITY JOURNAL; PROBABILITY; SEPSIS; SIBLING; SPINAL CORD DISEASE;

EID: 0034067082     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702392     Document Type: Article

References (60)

1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1555.
2. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease. Results of a BNLL randomized trial. Lancet 1993; 341: 1051-1054.
3. Stahel RA, Lorenz MJ, Pichert G et al. High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas. Cancer Treat Rev 1995; 21: 3-32.
4. Stahel RA, Jost LM, Honegger H et al. Randomized trial showing equivalent efficacy of Filgrastim 5 /ig/kg/d and 10 /ng/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas. J Clin Oncol 1997; 15: 1730-1735.
5. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry Data. J Clin Oncol 1992; 10: 1690-1695.
6. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has 'high-risk' disease? Blood 1994; 83: 1165-1173.
7. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193-1199.
8. Chopra R, McMillan AK, Linch DC et al. The place of highdose BEAM therapy and autologous bone marrow transplan-tation in poor-risk Hodgkin's disease. A single-center eightyear study of 155 patients. Blood 1993; 81: 1137-1145.
9. Nagler A, Ackerstein A, Or R et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferona in lymphoma patients post-autologous marrow or stem cell transplantation. Blood 1997; 89: 3951-3959.
10. Slavin S, Nagler A. New developments in bone marrow transplantation. Curr Opin Oncot 1991; 3: 254-271.
11. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs. leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Iinmiinol Immunother 1990; 31: 236-242.
12. Weiss L, Lubin I, Factorowich I et al. Effective graft versus leukemia effects independent of graft versus host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma (BCL1): role of cell therapy and recombinant IL-2. J Immunol 1994; 153: 2563-2567.
13. Slavin S, Weiss L, Morecki S et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TL1). Cancer Immunol Immunother 1981; 11: 155-158.
14. Or R, Nagler A, Ackerstein A et al. Allogeneic cell-mediated immunotherapy at the minimal residual disease stage following autologous stem cell transplantation for malignant lymphoma. Immunother 1998; 21: 447-453.
15. Papadopoulos EB, Landanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
16. Toren A, Or R, Ackerstein A, Nagler A. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT). Bone Marrow Transplant 1997; 20: 67-69.
17. Slavin S, Nagler A. Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma. Ann Oncol 1998; 9: S31-39.
18. Phillips GL, Herzig RH, Lazarus HM et al. High dose chemotherapy, fractionated total body irradiation and allogeneic marrow transplantation for malignant lymphoma. J din Oncol 1986; 4: 480-498.
19. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
20. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodskin's lymphoma. Blood 1994; 84: 1050-1055.
21. Verdonck LF, Dekker AW, Lokhorts HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 4201-4205.
22. Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 1995; 13: 596-602.
23. Van Besien W, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996; 100: 299-307.
24. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
25. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for
26. Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291-1296.
27. De Lima M, Van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for nonHodakin's lymphoma. Bone Marrow Transplant 1997; 19: 121-127.
28. Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodakin's lymphoma. Bone Marrow Transplant 1997; 20: 369-374.
29. Yang SW, Huang P, Plunkett W. Dual mode of inhibition of purified DNA ligase I from human cells by 9-ß-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 1992; 267: 2345-2349.
30. Huang P, Plunkett W. Action of 9-β-D-arabinofuranosyl-2fluoroadenine on RNA metabolism. Mol Pharmacol 1991; 39: 449-455.
31. Robertson LE, Chubb S, Meyn RE. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-β-D-arabinofuranosyl-2-fluoroadenine. Blood 1993; 81: 143-150.
32. Keating MJ. Fludarabine phosphate: current and future therapeutic applications. Semin Oncol 1993; 20: 1-31.
33. Keating MJ, Kantarjian H, O'Brien S et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991; 9: 44-49.
34. Keating MJ, Kantarjian H, Talpaz M et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19-25.
35. Redman JR, Cabanilias F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992; 10: 790-794.
36. Höchster HS, Kim K, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992; 10: 28-32.
37. Hiddemann W, Unterhalt M, Port C et al. Fludarabine singleagent therapy for relapsed low-grade non-Hodgkin's lymphoma: a phase II study of the German Low-Grade NonHodgkin's Lymphoma Study Group. Semin Oncol 1993; 20: 28-31.
38. Pigaditou A, Rohatiner AZS, Whelan JS et al. Fludarabine in low-grade lymphoma. Semin Oncol 1993; 20: 24-27.
39. Keating MJ. Immunosuppression with purine analogues -the flip side of the gold coin. Ann Oncol 1993; 4: 347-348.
40. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med 1998; 339: 1186-1193.
41. Slavin S, Nagler A, Naparstek E. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hématologie diseases. Blood 1998; 91: 756-763.
42. Or R, Weiss L, Teiman S, Polliack A. Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation. Blood 1997; 1: 471-472 (letter).
43. Gribben JG, Freedman AS, Woo SD et al. All advanced nonHodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275-3280.
44. Pugatsch T, Oppenheim A, Slavin S. Improved single step PCR assay for sex identification post allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996; 17: 273-275.
45. Nakamura Y, Leppert M, O'Connell P. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 1987; 235: 1616-1622.
46. Przepiorka DM, Weisdorf D, Martin P. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
47. Sullivan KM, Agura E, Anasetti C. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Oncol 1991; 28: 250-259.
48. Bearman SI, Appelbaum PR, Buckner CD. Regimen related toxicity in patients undergoing bone marrow transplantation. Clin Oncol 1988; 6: 1562-1568.
49. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 54: 457-481.
50. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human intedeukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
51. Nilsson SK, Dooner MS, Tiarks CY et al. Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model. Blood 1997; 89: 4013-4020.
52. Rao SS, Peters SO, Grillenden RB et al. Stem cell transplantation in the normal nonmyeloablated hosl: relationship between cell dose, schedule, and engrafiment. Exp Hematol 1997; 25: 114-121.
53. Girall S, Estey E, Albitar M et al. Engraflmenl of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs.-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
54. McSweeney PA, Wagner JL, Maloney DG el al. Outpalienl PBSC allografls using immunosuppression after low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood 1998; 92 (Suppl. 1): 519a (Abstr. 2133).
55. Woolfrey AE, Nash RA, Frangoul HA et al. Non-myeloablative transplant regimen used for induction of multi-lineage allogeneic hematopoietic mixed donor-host chimerism in patients with T cell immunodeficiency. Blood 1998; 92 (Suppl. 1): 520a (Abstr. 2135).
56. Juckett M, Rowlings P, Hessner M et al. T cell-depleted allogeneic bone marrow transplantation for high-risk nonHodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant 1998; 21: 893-899.
57. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
58. Falkenburg JHF, Jluin-Nelemans HC. Mismatched transplants for refractory lymphoma? Lancet 1999; 353: 1725-1726.
59. Aizawa S, Sado T. Graft-versus-leukemia effect in MHC-compatible and incompatible allogeneic bone marrow transplantations of radiation-induced leukemia-bearing mice. Transplantation 1991; 51: 885-889.
60. Sykes M, Sachs DH. Genetic analysis of anti-leukemic effect of mixed allogeneic bone marrow transplantation. Transplant Proc 1989; 21: 3022-3024.